EMG Announces Appointment of Shaun Gregory as New Group Chief Executive Officer
11.5.2021 09:30:00 EEST | Business Wire | Press release
EMG, a leading global provider of broadcast facilities and media solutions, announced today that Shaun Gregory will join the company as Group Chief Executive Officer starting May 17th 2021. Gregory is a seasoned executive with over 30 years of experience in the media, telecommunications & broadcasting industries. He has served as Chief Executive Officer for some of the fastest growing companies, both in Europe and globally.
Under his leadership, EMG will continue the development of its ambitious transformation strategy. He will succeed co-CEO Patrick van den Berg who after 15 years serving in various leadership positions at EMG will take on a new professional challenge while co-CEO François-Charles Bideaux will become advisor to the CEO & EMG board focusing on specific areas such as sales, technology and M&A.
Most recently, Gregory was CEO of media localization company IYUNO Media Group (formerly BTI Studios) which spans 46 countries and 88 language types, servicing the world’s leading entertainment brands, including Netflix and Disney. In this role, he was responsible for developing a market leading strategy, transforming the business and the creation of a new global market leader in media localisation. Prior to IYUNO, Gregory was Chief Executive Officer at Exterion Media, Europe’s largest privately held out of home advertising company. At Exterion Media, Shaun was appointed Chief Executive in 2014, and was successfully awarded the world’s biggest outdoor advertising contract, The London Underground. Exterion operated across markets in Europe, including the UK, Ireland, Netherlands, France and Spain. Both companies enjoyed market beating growth under private equity ownership, with Exterion sold to Global in 2018.
Prior to IYUNO and Exterion, Gregory was the Global Managing Director of Telefonica’s media and content businesses. He was responsible for 34 markets, including most of Latin America, having emerged out of his UK role at O2. He was credited with a number of launches, including O2 Priority in the UK, and created new and innovative ways of delivering content to consumers. Before his time at Telefonica he spent almost 15 years at EMAP, Europe’s fastest growing media company where he was a key architect in the company’s digital transformation, winning several licences (analogue and digital), spanning radio and television. In addition, EMAP was pivotal in the launch of the UK’s digital terrestrial television platform Freeview.
Patrick van den Berg commented: “First of all a warm welcome to Shaun. After my 15 years in different leadership positions within EMG and finally as co-CEO, it is important for me that a seasoned executive with a broad and international experience takes over as CEO. Given Shaun’s background I am confident that he will lead EMG into future successes. I would like to take this opportunity to thank everybody at EMG as well as our founders and investors, for everything we realized and for the group we built together. It has been a great adventure and although it is time for me to take on a new professional challenge, I will surely keep on following the amazing company which is EMG.”
“On behalf of the board of EMG, I would like to thank Patrick for his contribution in making EMG the success it is today and wish him all the best in his next challenge,” added Fabrice Fouletier, Partner at PAI Partners, the majority shareholder in EMG. “We are thrilled to have appointed someone with Shaun’s credentials. He has an excellent track record, that spans over 30 years, in both listed and private equity backed companies. He has operated at the most senior level of some of the fastest growing companies in our sector and has done that successfully through innovation and a relentless focus on growth. His international and transformation experience will provide a strong platform for EMG, and I am confident that he will lead the company into a new and exciting chapter.”
Shaun Gregory said: “I’m excited to be joining the EMG Team, and can’t wait to continue the great work that’s been going on there. I see these as pivotal moments in the broadcasting and live events industry. As the world returns to normality, the appetite for what EMG delivers to people around the globe will become ever more important. EMG have played an acute role in getting people through the challenges of the pandemic, delivering some of the world’s most prestigious sporting events. As we look forward to happier times, I’m thrilled to be part of a new growth story and delivering the raw emotions and experiences to audiences around the world.”
He added: “The industry will need to innovate with new technological solutions, and EMG are already leading the way. Our customers and partners will have changing needs, as the landscape develops, and I’m looking forward to us being ahead of the curve. It’s not just about innovation, it’s also about taking a very ‘customer-centric’ approach to everything we do, and that’s one thing that EMG is all about – great customer service, innovation and ultimately a world class delivery. I’m very proud to be joining the Team, and providing the Leadership for the next chapter.”
Gregory has also served as a non-Executive Director of both listed and private equity backed companies. He also serves on the Childline Board (NSPCC) and the Advisory Board for The Sheffield Children’s Hospital. He is originally from Yorkshire in the UK, has two daughters and currently lives in London.
About EMG
EMG is a leading global provider of broadcast services and media solutions for live sports, entertainment and events, active in 10 countries: France, Belgium, the Netherlands, Germany, United Kingdom, Switzerland, Italy, Luxembourg, the USA & Australia. Constantly proposing state-of-the-art technologies through highly experienced teams, EMG is a valued partner for major international events, including sport (Tour de France, Football World Cup and Formula One…) live events (Eurovision, Royal Weddings, Concerts…) and entertainment (The Voice, Masterchef, the X-Factor…).
About PAI Partners
PAI Partners is a leading European private equity firm with offices in Paris, London, Luxembourg, Madrid, Milan, Munich, New York and Stockholm. It manages €14.7 billion of dedicated buyout funds and, since 1994, has completed 84 transactions in 11 countries, representing over €60 billion in transaction value. PAI Partners is characterised by its industrial approach to ownership combined with its sector-based organisation. It provides the companies it owns with the financial, operational and strategic support required to pursue their development and enhance value creation.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210510005202/en/
Contact information
Press
Pauline Bénéat
pauline.beneat@emglive.com
+32 (0) 472 188 495
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
